Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mutational Landscape of Women Suffering from Metastatic Ovarian Cancer Before Poly (ADP-ribose) Polymerase Inhibitors Maintenance Treatment and During Treatment. Incidence of Therapy-related Hematological Neoplasms.

NCT06785077 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT06785077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06785077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mutational Landscape of Women Suffering from Metastatic Ovarian Cancer Before Poly (ADP-ribose) Polymerase Inhibitors Maintenance Treatment and During Treatment. Incidence of Therapy-related Hematological Neoplasms.
Lead sponsor
European Institute of Oncology
Phase
Not applicable
Overall status
Recruiting
Start date
October 2, 2020
Completion date
April 30, 2028
Enrollment
157 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, myeloid dysplasia, ovarian epithelial cancer